Prevention and treatment of cancers by tumor antigen-expressing Staphylococcus epidermidis

Oliver Kepp; Laurence Zitvogel; Guido Kroemer

doi:10.1080/2162402X.2023.2212547

Prevention and treatment of cancers by tumor antigen-expressing Staphylococcus epidermidis

Oncoimmunology. 2023 May 15;12(1):2212547. doi: 10.1080/2162402X.2023.2212547. eCollection 2023.

Authors

Oliver Kepp^{1

2}, Laurence Zitvogel^{3

4

5

6}, Guido Kroemer^{1

2

7}

Affiliations

¹ Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France.
² Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.
³ Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
⁴ Université Paris Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.
⁵ Equipe labellisée par la Ligue contre le Cancer, INSERM U1015, Villejuif, France.
⁶ Department of Biology, Center of Clinical Investigations in Biotherapies of Cancer (CICBT) BIOTHERIS, Villejuif, France.
⁷ Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Abstract

In a recent paper in Science, Chen et al. reported the genetic engineering of S. epidermidis expressing tumor cross-reactive antigens that trigger T cell responses and exhibit anticancer effects after topical administration. Here we discuss direct local effects and indirect systemic effects of exposure to engineered S. epidermidis strains.

Keywords: Immunity; Immunotherapy; Microbiome.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antigens, Neoplasm / genetics
Humans
Neoplasms* / genetics
Neoplasms* / prevention & control
Staphylococcus epidermidis* / genetics

Substances

Antigens, Neoplasm

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.